Skip to content
Screener

Personalis, Inc. PSNL Net Change in Cash

Net Change in Cash at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
$233M
NeoGenomics logo
NeoGenomicsNEO
-$604K+99.7%
Illumina logo
IlluminaILMN
-$49M+72.6%
Veracyte logo
VeracyteVCYT
-$99.43M-88.1%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$4.42M
Guardant Health logo
Guardant HealthGH
$612.02M+252%

Other financials

Income statement

See full
Revenue$15.5M-24.9%
Gross profit$281.0K-96.1%
Operating income-$32.2M-81.7%
Net income-$30.0M-90.7%
EPS (diluted)-$0.29-61.1%

Balance sheet

See full
Cash & equivalents$73.6M+3.7%
Total debt$39.0M-6.2%
Total equity$254.8M+22.9%
Total assets$325.4M+19.1%

Cash flow

See full
Operating cash flow-$22.5M-25.1%
CapEx$3.2M+27.1%
Free cash flow-$25.7M-25.4%

Valuation

See full
Market cap$1.51B+279%
Enterprise value$1.48B+283%
P/S23.4×+18.5×

Profitability

See full
Gross margin13.7%-19.6pp
Operating margin-158.9%-5,457pp
Net margin-148.1%+154pp
FCF margin-131.2%-453pp

Returns & leverage

See full
Return on equity-41.4%-6.7pp
Debt / equity0.2×0.0×
Current ratio6.6×-0.3×

Where this comes from

Reported directly by Personalis, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Personalis, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211896
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from issuance of common stock under equity incentive plans281132
Net cash provided by financing activities17,83020,087
Effect of exchange rates on cash, cash equivalents and restricted cash92
Net change in cash, cash equivalents and restricted cash(50,651)(20,414)
Cash, cash equivalents and restricted cash, beginning of period126,03593,205
Cash, cash equivalents and restricted cash, end of period$75,384$72,791
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents$73,594$71,001

Item 1. Financial Statements

FAQ

What is Personalis, Inc.'s net change in cash?
Personalis, Inc. (PSNL) reported net change in cash of -$50.65M in Q1 2026.
How has Personalis, Inc.'s net change in cash changed year-over-year?
Personalis, Inc.'s net change in cash decreased by 148.1% year-over-year, from -$20.41M to -$50.65M.
What is the long-term trend for Personalis, Inc.'s net change in cash?
Over 2 years (2023 to 2025), Personalis, Inc.'s net change in cash has grown at a 1.1% compound annual growth rate (CAGR), from -$32.14M to $32.83M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Personalis, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude